Kevin Crowley

Kevin is a board member of TREBEL, a position he has held since 2017. He is a Senior Managing Director, Investments, at Connecticut Innovations (CII). Since joining CII in 2006, Kevin has led investments in , Torigen Pharmaceuticals, Affinimark Technologies, Cara Therapeutics (IPO), CaroGen Corporation, Discover Video, HistoRx (sold to Genoptix), Intelligent Clearing Network, Oil Purification Systems, Oxford Performance Materials, Perosphere, Precipio Diagnostics (IPO), Rapid Oxygen and Solais Lighting (sold to PowerSecure),BioWave Corporation, Point Pickup, WellLinks, Inc,Mininvasive Orthopedics Solutions, OmniCyte and others. He was on the board of Standing Stone when it was sold to Alere.

Kevin is a founding member and on the board of the UConn Innovation Fund, a partnership with Webster Bank, UConn and CII that makes investments in UConn-related technologies.

He managed CII’s $46 million BioFacilities Fund, which invested in wet laboratory space for bioscience companies, and managed CII’s two incubator laboratories in Science Park in New Haven. Kevin was also involved in the establishment of the Connecticut Stem Cell Fund and managed CII’s PreSeed program, which makes investment in very early-stage companies with small convertible-debt instruments.